vs
Side-by-side financial comparison of EXELIXIS, INC. (EXEL) and Paymentus Holdings, Inc. (PAY). Click either name above to swap in a different company.
EXELIXIS, INC. is the larger business by last-quarter revenue ($598.7M vs $330.5M, roughly 1.8× Paymentus Holdings, Inc.). EXELIXIS, INC. runs the higher net margin — 40.8% vs 6.3%, a 34.6% gap on every dollar of revenue. On growth, Paymentus Holdings, Inc. posted the faster year-over-year revenue change (28.1% vs 5.6%). EXELIXIS, INC. produced more free cash flow last quarter ($332.4M vs $45.0M). Over the past eight quarters, Paymentus Holdings, Inc.'s revenue compounded faster (33.7% CAGR vs 18.7%).
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Paymentus Holdings, Inc. is a leading cloud-based bill payment and customer engagement technology provider. It offers integrated digital payment solutions, billing automation tools, and self-service portals for enterprises across utilities, financial services, government, healthcare, and telecommunications segments, primarily operating in the North American market.
EXEL vs PAY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $598.7M | $330.5M |
| Net Profit | $244.5M | $20.7M |
| Gross Margin | 95.6% | 25.4% |
| Operating Margin | 39.3% | 7.3% |
| Net Margin | 40.8% | 6.3% |
| Revenue YoY | 5.6% | 28.1% |
| Net Profit YoY | 74.8% | 57.2% |
| EPS (diluted) | $0.89 | $0.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $598.7M | — | ||
| Q4 25 | $597.8M | $330.5M | ||
| Q3 25 | $568.3M | $310.7M | ||
| Q2 25 | $555.4M | $280.1M | ||
| Q1 25 | $566.8M | $275.2M | ||
| Q4 24 | — | $257.9M | ||
| Q3 24 | $539.5M | $231.6M | ||
| Q2 24 | $637.2M | $197.4M |
| Q1 26 | $244.5M | — | ||
| Q4 25 | $193.6M | $20.7M | ||
| Q3 25 | $184.8M | $17.7M | ||
| Q2 25 | $159.6M | $14.7M | ||
| Q1 25 | $139.9M | $13.8M | ||
| Q4 24 | — | $13.1M | ||
| Q3 24 | $118.0M | $14.4M | ||
| Q2 24 | $226.1M | $9.4M |
| Q1 26 | 95.6% | — | ||
| Q4 25 | 96.9% | 25.4% | ||
| Q3 25 | 96.6% | 24.1% | ||
| Q2 25 | 96.5% | 25.5% | ||
| Q1 25 | 96.5% | 24.0% | ||
| Q4 24 | — | 25.6% | ||
| Q3 24 | 96.8% | 26.2% | ||
| Q2 24 | 97.2% | 29.8% |
| Q1 26 | 39.3% | — | ||
| Q4 25 | 39.6% | 7.3% | ||
| Q3 25 | 37.6% | 6.4% | ||
| Q2 25 | 33.6% | 5.7% | ||
| Q1 25 | 28.8% | 5.7% | ||
| Q4 24 | — | 5.5% | ||
| Q3 24 | 25.2% | 5.2% | ||
| Q2 24 | 43.3% | 5.2% |
| Q1 26 | 40.8% | — | ||
| Q4 25 | 32.4% | 6.3% | ||
| Q3 25 | 32.5% | 5.7% | ||
| Q2 25 | 28.7% | 5.3% | ||
| Q1 25 | 24.7% | 5.0% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | 21.9% | 6.2% | ||
| Q2 24 | 35.5% | 4.7% |
| Q1 26 | $0.89 | — | ||
| Q4 25 | $0.69 | $0.16 | ||
| Q3 25 | $0.65 | $0.14 | ||
| Q2 25 | $0.55 | $0.11 | ||
| Q1 25 | $0.47 | $0.11 | ||
| Q4 24 | — | $0.11 | ||
| Q3 24 | $0.40 | $0.11 | ||
| Q2 24 | $0.77 | $0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | $320.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.2B | $560.4M |
| Total Assets | $2.8B | $667.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.1B | — | ||
| Q4 25 | $988.5M | $320.9M | ||
| Q3 25 | $791.1M | $287.9M | ||
| Q2 25 | $1.0B | $266.4M | ||
| Q1 25 | $1.1B | $245.8M | ||
| Q4 24 | — | $205.9M | ||
| Q3 24 | $1.2B | $187.5M | ||
| Q2 24 | $1.0B | $188.8M |
| Q1 26 | $2.2B | — | ||
| Q4 25 | $2.2B | $560.4M | ||
| Q3 25 | $2.0B | $537.4M | ||
| Q2 25 | $2.1B | $516.7M | ||
| Q1 25 | $2.2B | $500.4M | ||
| Q4 24 | — | $485.6M | ||
| Q3 24 | $2.3B | $468.8M | ||
| Q2 24 | $2.1B | $451.6M |
| Q1 26 | $2.8B | — | ||
| Q4 25 | $2.8B | $667.9M | ||
| Q3 25 | $2.7B | $644.4M | ||
| Q2 25 | $2.8B | $609.5M | ||
| Q1 25 | $2.9B | $590.9M | ||
| Q4 24 | — | $576.2M | ||
| Q3 24 | $3.0B | $552.9M | ||
| Q2 24 | $2.8B | $527.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $333.5M | $45.1M |
| Free Cash FlowOCF − Capex | $332.4M | $45.0M |
| FCF MarginFCF / Revenue | 55.5% | 13.6% |
| Capex IntensityCapex / Revenue | 0.2% | 0.0% |
| Cash ConversionOCF / Net Profit | 1.36× | 2.18× |
| TTM Free Cash FlowTrailing 4 quarters | $875.8M | $161.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $333.5M | — | ||
| Q4 25 | $290.3M | $45.1M | ||
| Q3 25 | $49.0M | $35.1M | ||
| Q2 25 | $211.4M | $31.5M | ||
| Q1 25 | $240.3M | $50.4M | ||
| Q4 24 | — | $27.9M | ||
| Q3 24 | $271.3M | $6.7M | ||
| Q2 24 | $119.5M | $18.0M |
| Q1 26 | $332.4M | — | ||
| Q4 25 | $288.8M | $45.0M | ||
| Q3 25 | $46.2M | $35.0M | ||
| Q2 25 | $208.5M | $31.4M | ||
| Q1 25 | $236.3M | $50.4M | ||
| Q4 24 | — | $27.8M | ||
| Q3 24 | $263.1M | $6.7M | ||
| Q2 24 | $113.0M | $17.8M |
| Q1 26 | 55.5% | — | ||
| Q4 25 | 48.3% | 13.6% | ||
| Q3 25 | 8.1% | 11.3% | ||
| Q2 25 | 37.5% | 11.2% | ||
| Q1 25 | 41.7% | 18.3% | ||
| Q4 24 | — | 10.8% | ||
| Q3 24 | 48.8% | 2.9% | ||
| Q2 24 | 17.7% | 9.0% |
| Q1 26 | 0.2% | — | ||
| Q4 25 | 0.2% | 0.0% | ||
| Q3 25 | 0.5% | 0.0% | ||
| Q2 25 | 0.5% | 0.0% | ||
| Q1 25 | 0.7% | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | 1.5% | 0.0% | ||
| Q2 24 | 1.0% | 0.1% |
| Q1 26 | 1.36× | — | ||
| Q4 25 | 1.50× | 2.18× | ||
| Q3 25 | 0.27× | 1.98× | ||
| Q2 25 | 1.32× | 2.14× | ||
| Q1 25 | 1.72× | 3.65× | ||
| Q4 24 | — | 2.12× | ||
| Q3 24 | 2.30× | 0.47× | ||
| Q2 24 | 0.53× | 1.93× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXEL
| Cabometyx | $544.7M | 91% |
| Collaboration | $52.1M | 9% |
| Collaborative Arrangementwith Takeda | $5.9M | 1% |
| Cometriq | $1.8M | 0% |
PAY
| Payment Transaction Processing Revenue | $326.9M | 99% |
| Other | $3.5M | 1% |
